Rouzier R, Uzan C, Collinet P
Service de Gynécologie-Obstétrique, Centre Hospitalier Intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.
J Gynecol Obstet Biol Reprod (Paris). 2007 Feb;36(1):13-8. doi: 10.1016/j.jgyn.2006.10.006. Epub 2007 Jan 17.
Human papillomavirus (HPV) are responsible of an important morbidity and mortality. HPV is a significant source of morbidity and mortality. HPV is the most common sexually transmitted infection: adolescents are at high-risk for HPV acquisition. Biologic and epidemiologic studies have demonstrated that HPV infection is a necessary but non-sufficient cause of cervical cancer and genital warts. The vast majority of cervical cancers contain high-risk HPV type and approximately 70% contain HPV types 16 or 18. HPV types 6 or 11 are responsible for approximately 90% of genital warts. Thus, a vaccine that could prevent. Prophylactic vaccines based on the use of virus-like particles (VLPs) obtained by auto-assembly of L1 are under clinical trials. Two vaccines are currently evaluated: Cervarix (GlaxoSmithKline Biologics), a bivalent vaccine against HPV 16 and 18, and Gardasil (Merck & Co) a quadrivalent vaccine against HPV 16, 18, 6, and 11. Phase I, II and III studies have demonstrated that both vaccines are well tolerated and provide an excellent immunogenicity. With approximately 5-year follow-up, both vaccines have been effective in preventing persistent infection with targeted HPV types and in preventing cervical intraepithelial lesions. The optimal target for vaccination is probably 12-year-old girls.
人乳头瘤病毒（HPV）会导致严重的发病和死亡。HPV是发病和死亡的一个重要原因。HPV是最常见的性传播感染：青少年感染HPV的风险很高。生物学和流行病学研究表明，HPV感染是宫颈癌和尖锐湿疣的必要但不充分病因。绝大多数宫颈癌含有高危型HPV，约70%含有16型或18型HPV。6型或11型HPV约导致90%的尖锐湿疣。因此，一种能够预防的疫苗。基于L1自组装获得的病毒样颗粒（VLP）的预防性疫苗正在进行临床试验。目前正在评估两种疫苗：希瑞适（葛兰素史克生物制品公司），一种针对HPV 16和18的二价疫苗，以及佳达修（默克公司），一种针对HPV 16、18、6和11的四价疫苗。I期、II期和III期研究表明，这两种疫苗耐受性良好，具有出色的免疫原性。经过约5年的随访，这两种疫苗在预防目标HPV型别的持续感染和预防宫颈上皮内病变方面均有效。疫苗接种的最佳目标可能是12岁的女孩。
